Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

The addition of high-dose cytarabine to rituximab/bendamustine (RB) induction could improve outcomes for transplant-eligible patients with mantle cell lymphoma (MCL). We conducted a pooled analysis of 2 phase 2 trials and an off-trial cohort each testing 3 cycles of RB and 3 cycles of rituximab/high...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Merryman, Reid W., Edwin, Natasha, Redd, Robert, Bsat, Jad, Chase, Matthew, LaCasce, Ann, Freedman, Arnold, Jacobson, Caron, Fisher, David, Ng, Samuel, Crombie, Jennifer, Kim, Austin, Odejide, Oreofe, Davids, Matthew S., Brown, Jennifer R., Jacene, Heather, Cashen, Amanda, Bartlett, Nancy L., Mehta-Shah, Neha, Ghobadi, Armin, Kahl, Brad, Joyce, Robin, Armand, Philippe, Jacobsen, Eric
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065472/
https://ncbi.nlm.nih.gov/pubmed/32126141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001355
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars